{"id":"W4378530156","doi":"10.1016/j.ctrv.2023.102584","title":"The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma – A systematic review","year":2023,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary; University of British Columbia; BC Cancer Agency; Princess Margaret Cancer Centre; Juravinski Cancer Centre; Dalhousie University; University of Toronto; McMaster University","funders":"","keywords":"Sorafenib; Medicine; Bevacizumab; Oncology; Durvalumab; Atezolizumab; Internal medicine; Hepatocellular carcinoma; Clinical trial; Regimen; Immunotherapy; Cancer; Nivolumab; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001395256,0.0009839089,0.008380958,0.0003585477,0.0001593183,0.00002548228,0.0003319081,0.0002710584,0.00003816522],"category_scores_gemma":[0.000344476,0.0005203222,0.003112357,0.001854635,0.0001118839,0.00007634117,0.00008209089,0.0003217931,0.0002844086],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004796758,"about_ca_system_score_gemma":0.001232135,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005301852,"about_ca_topic_score_gemma":0.0001154656,"domain_scores_codex":[0.9930938,0.001050788,0.004161692,0.0007201447,0.0004317239,0.0005418431],"domain_scores_gemma":[0.9953654,0.0004125701,0.002242071,0.001632563,0.0001707281,0.0001766517],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.000009315079,0.0003575027,0.001223255,0.8662778,0.0005459589,0.00008557326,0.00004853126,2.010493e-8,0.000001664685,0.00006834233,0.00008579148,0.1312963],"study_design_scores_gemma":[0.001010311,0.0003419468,0.00002192882,0.6872427,0.01611878,0.00003525076,0.00002234662,0.00002547012,0.00001354178,0.0000110978,0.2948548,0.0003018785],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00008645738,0.9697098,0.00000267007,0.00016266,0.0002903676,0.02941439,0.00008880139,0.00006440286,0.0001804707],"genre_scores_gemma":[0.0004347801,0.9600026,0.00003501125,0.00001582395,0.00007716877,0.03676307,0.0004520469,0.0001263834,0.002093098],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.294769,"threshold_uncertainty_score":0.9997249,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1175993671776607,"score_gpt":0.3477802134063483,"score_spread":0.2301808462286876,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}